[PRNewswire] Novavax to Participate in Fireside Chat at Devex @ UNGA 76

최정환 2021. 9. 21. 11:56
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

(GAITHERSBURG, Md., Sept. 20, 2021 PRNewswire=연합뉴스) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion along with fostering global vaccine access.

Interview details are as follows:

Date: Tuesday, September 21, 2021

Time: 8:50 - 9:05 a.m.

Location: Livestream [https://pages.devex.com/devex-at-unga-76.html ]

Title: Fireside chat: A status report on the COVID-19 vaccine rollout

Novavax panelist: John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Moderator: Jenny Lei Ravelo, Senior Reporter, Devex

For more information or to register for the fireside chat, visit:


About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter [https://twitter.com/novavax ] and LinkedIn [https://www.linkedin.com/company/novavax ].



Novavax, Inc.

Erika Schultz | 240-268-2022


Solebury Trout

Alexandra Roy | 617-221-9197



Alison Chartan | 240-720-7804

Laura Keenan | 202-709-7521


Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

Novavax Logo

Source: Novavax, Inc.

[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.


출처 : PRNewswire 보도자료

Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?